Biotherapeutic pipelines don’t just juggle monoclonal antibodies anymore, they need to be ready for protein conjugates like ADCs and for teeny tiny peptides. Even beyond new modalities, automation is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results